Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · IEX Real-Time Price · USD
11.16
+0.02 (0.18%)
Apr 23, 2024, 9:30 AM EDT - Market open
Company Description
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases.
It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.
The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020.
The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Mineralys Therapeutics, Inc.
| Country | United States |
| Founded | 2019 |
| IPO Date | Feb 10, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Jon Congleton |
Contact Details
Address: 150 N. Radnor Chester Road, Suite F200 Radnor, Pennsylvania 19087 United States | |
| Phone | (888) 378-6240 |
| Website | mineralystx.com |
Stock Details
| Ticker Symbol | MLYS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001933414 |
| ISIN Number | US6031701013 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jon Congleton | Chief Executive Officer and Director |
| Adam Scott Levy | Chief Financial Officer and Secretary |
| Dr. David M. Rodman M.D. | Chief Medical Officer |
| Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D. | Founder and Executive Chairman |
| Cindy Berejikian | Executive Vice President of Operations |
| Sarah Foster | Vice President of Human Resources |
| Dr. Robert McKean Ph.D. | Senior Vice President of CMC |
| Danielle Bradbury | Senior Vice President of Quality Assurance |
| Jeffrey N. Fellows | Senior Vice President of Regulatory Affairs |
| Jessica Ibbitson | Senior Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2024 | EFFECT | Notice of Effectiveness |
| Apr 11, 2024 | 424B5 | Filing |
| Apr 9, 2024 | ARS | Filing |
| Apr 9, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 9, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 4, 2024 | 8-K | Current Report |
| Mar 29, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Mar 21, 2024 | 8-K | Current Report |
| Mar 21, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 21, 2024 | 10-K | Annual Report |